Nurix therapeutics (NRIX) CSO Hansen sells $51k in stock

Published 30/07/2025, 23:58
Nurix therapeutics (NRIX) CSO Hansen sells $51k in stock

Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biotechnology company with a market capitalization of $906 million, sold 4,308 shares of common stock on July 30, 2025, for approximately $51,743. According to InvestingPro analysis, the company currently shows signs of being undervalued despite facing significant cash burn challenges. The shares were sold at a weighted average price of $12.011, with prices ranging from $11.78 to $12.315. The transaction occurred with the stock trading significantly below its 52-week high of $29.56, amid notable price volatility that has resulted in a 43% decline over the past year.

On the same day, Hansen also acquired a total of 11,815 shares of Nurix Therapeutics common stock through the exercise of restricted stock units. These transactions did not involve any payment.

Following these transactions, Hansen directly owns 69,023 shares of Nurix Therapeutics.

In other recent news, Nurix Therapeutics has been the subject of several analyst updates following its second-quarter financial results. Morgan Stanley (NYSE:MS) adjusted its price target for Nurix to $16.00 from $17.00, citing higher anticipated spending for planned pivotal trials. UBS also lowered its price target to $26.00 from $30.00, attributing the change to increased operational expenses. Despite these adjustments, both firms maintained their respective ratings, with Morgan Stanley keeping an Equalweight rating and UBS a Buy rating. Stifel remains optimistic about Nurix, reiterating its Buy rating and a $35.00 price target, projecting potential peak sales exceeding $4.5 billion for the company’s lead drug candidate. Goldman Sachs initiated coverage on Nurix with a Buy rating and a notably high price target of $182.00, expecting the launch of Crenessity to counterbalance potential challenges to Ingrezza growth. These developments highlight differing perspectives on Nurix’s financial outlook and strategic plans.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.